fig4

Figure 4. Differential abundance of immune cells (immune score) in tissue microenvironment between sample groups classified by patient age, sample type, or metastasis factors. (A) Immune scores for tumor and matched benign prostatic tissue samples from 119 patients in the COH data set were used to generate dot and box plots. Compared to matched benign prostatic tissue, tumor tissues with Gleason scores of 6 and 7 from young patients (≤ 50 years) (black) showed significantly increased abundance of immune cells (blue vs. black, P < 0.01), whereas old patients (> 70 years) showed non-significant tumor-versus-matched-benign difference in abundance of immune cells (red vs. green, P > 0.10). (B) Immune scores for 1232 primary tumor samples from five GRID data sets were used to generate plots. Compared to tumor tissues from young patients (≤ 55 years) without metastasis, tumor tissues from young patients with metastasis showed significantly (blue vs. black, P = 0.02) increased abundance of immune cell types; patients with middle age (56-70 years) also showed highly significant but a smaller with-and-without- metastasis difference (cyan vs. orange, P < 0.0001 in abundance of immune cell types than young patients (≤ 55 years); old patients (≥ 70 years) (green vs. red, P = 0.21) had no significant difference in abundance of immune cell types related to metastasis status.